Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HBV most commonly refers to the hepatitis B virus, a DNA virus that infects the liver and can cause both acute and chronic liver disease. It is not itself a drug but rather the pathogen targeted by several antiviral drugs and vaccines. In some contexts, "HBV" may be used as shorthand for "hepatitis B vaccine," which is used to prevent infection with hepatitis B virus. The main mechanism of action for hepatitis B vaccines is to stimulate an immune response against the surface antigen of HBV, thereby conferring immunity. Approved vaccines include recombinant protein-based formulations such as Engerix-B, Heplisav-B, and Recombivax HB[8]. These are indicated for prevention of hepatitis B infection in adults and children.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on HBV.